ClinicalTrials.gg
RecruitingNCT07040046Updated Jun 26, 2025

HS-10542 Study in Healthy Participants

A Phase 1 interventional study of HS-10542 and HS-10542 Placebo in Healthy, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, dose escalation phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and the food effect on the pharmacokinetics of HS-10542 in healthy participants.

Read the detailed description

This study consists of two parts, of which the Part I consists of the single ascending dose (SAD) study and the food effect (FE) study, while the Part II consists of the multiple ascending dose (MAD) study. The Part I and Part II form this randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, PK and PD characteristics, as well as the food effect on pharmacokinetics of HS-10542 in Chinese healthy adult participants after single and multiple oral doses.

02

Conditions studied

  • Healthy

Keywords

  • HS-10542
  • phase 1
  • Healthy
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between 18 and 64 years of age (critical values inclusive) when signing the form.
  2. (BMI = weight/height2) ≥ 19 kg/m2 and ≤ 28 kg/m2 at screening, and body weight ≥ 50 kg for men and ≥ 45 kg for women.
  3. Physical examination, laboratory tests, 12-lead , abdominal B-ultrasound and anteroposterior and lateral chest X-ray (or CT) examination showed no abnormality, or slight abnormality but with no clinical significance as judged by the investigator, or slight abnormality but with controllable risk as judged by the investigator, and communication with the sponsor 's medical and pharmacological personnel is required when necessary;
  4. Female participants are required to agree to practice highly effective from 2 weeks before screening until 60 days after the last dose:
  5. Male participants of are required to agree to practice highly effective contraception from the date of signing the informed consent until 120 days after the last dose; male participants of non-childbearing potential (e.g, having undergone effective sterilization) are required to agree to use additional highly effective contraception in the event of uncertainty about the presence of sperm.
  6. Participants should be able to complete vaccinations against Neisseria meningitidis (types A, C, Y, and W-135) and streptococcus pneumoniae at least 2 weeks prior to the first dose, and if participants have previously received the above vaccines, antibody titers or vaccine manufacturer information should be provided, and booster vaccinations should be completed as needed according to local practice guidelines in the opinion of the investigator to obtain adequate protection during the trial.
  7. The participants are able to communicate clearly with the investigator, understand and comply with the requirements of this trial, have a comprehensive understanding of the study content, process and possible adverse reactions, and sign the informed consent forms voluntarily.

Exclusion criteria

Exclusion Criteria:

  1. Consumed any caffeinated, tea, alcohol, xanthine-rich foods or beverages within 24 hours before administration.
  2. Consumed foods known to alter hepatic enzyme activity (eg, pitaya, grapefruit, Seville oranges, etc) and their juice drinks within 1 week before administration.
  3. Abnormal vital signs, physical examination, laboratory tests, 12-lead , chest anteroposterior X-ray/CT examination, abdominal ultrasonography, etc. at the time of screening are and, as assessed by the investigator, may increase the risk for the participant or affect the interpretation of the study results, which include but are not limited to:

    1. Abnormal liver function: (ALT) or aspartate aminotransferase (AST) or total (TBiL) ≥ 1.5 times .
    2. Abnormal renal function: \< 60 mL/min/1.73 m2 at screening or abnormal renal function as judged by the investigator, calculated using the estimation formula of Chronic Kidney Disease Epidemiology Collaboration 2021 (CKD-EPI): eGFR (mL/min/1.73 m2) .
    3. Abnormal ECG: The absolute value of (QT interval corrected by Fridericia 's formula [QT/RR0.33]) > 450 msec for males and > 470 msec for females; or other clinically significant abnormalities as judged by the investigator.
  4. Positive virus surface antigen (HBsAg), or negative HBsAg but positive hepatitis B core antibody (HBcAb), or positive Ab, or positive result of any test for antibody or Treponema pallidum-specific antibody at screening and is assessed by the investigator as inappropriate to participate in this trial.
  5. participants with inactive, active or latent tuberculosis infection (indicated by tuberculosis on chest X-ray or CT, or positive T-SPOT.TB result) at screening who are assessed as inappropriate for participation in this trial by the investigator.
  6. Women with a positive blood pregnancy test result at screening, breastfeeding women, or participants planning to become pregnant during the trial.
  7. Used any systemic medication or food (e.g, prescription drugs, over-the-counter drugs, Chinese herbal medicines, health products, special medical supplies, formulas, etc) that could affect the metabolism of drug during the or 5 half-lives (whichever is longer) of a particular drug prior to screening, or participants who are unwilling to undergo washout and discontinue such medication throughout the trial and are assessed as inappropriate for participation in this trial by the investigator. Washout periods for systemic medications or food are detailed in Section 6.7.
  8. Those who have been vaccinated with vaccines other than those specified in this protocol within 1 month before screening or are scheduled to be vaccinated within 1 month after the end of the administration.
  9. Those who have participated in a clinical trial involving an intervention with another drug or medical device and received an investigational product or use of a medical device within 1 month prior to screening or within 7 half-lives of the other investigational product, whichever is longer.
  10. Those who have donated blood or lost blood ≥ 450 mL within 3 months prior to screening, or planning to donate blood during the trial and at the end or within 3 months of the trial.
  11. Those who have a known history of smoking (> 5 cigarettes per day on average) within 3 months prior to screening.
  12. Those with diseases or medical conditions that may affect the absorption, distribution, metabolism and excretion of oral drugs within 3 months before screening, such as inflammatory bowel disease, peptic ulcer, gastroesophageal reflux disease, chronic diarrhea, subtotal gastrectomy, etc.
  13. Those who have a known history of drug abuse/abuse within 6 months prior to screening, or test positive for drug abuse at screening.
  14. Those who have a known history of alcohol dependence (an average of ≥ 14 units of alcohol per week, each unit being equivalent to 285 mL of beer, 125 mL of wine, or 25 mL of liquor) within 6 months prior to screening, or a positive breath alcohol test at screening.
  15. Those who have undergone ≥ Grade 2 surgery within 6 months before screening, or plan to have surgery or be hospitalized during the trial.
  16. Those who have a previous history of severe drug, food or environmental allergy, or known to the active substance and of the investigational product (including HS-10542 and placebo).
  17. Those with a previous history of capsular microorganisms (e.g., meningococcus or pneumococcus) infection, or those with a history of close contact with individuals infected with meningococcal.
  18. Those who have difficulty in swallowing solid preparations such as tablets and capsules.
  19. Participants who have difficulty in blood collection, and cannot tolerate multiple venous blood draws or have any to blood collection.
  20. Participants with special dietary requirements or inability to comply with the dietary requirements of the study site.
  21. As judged by the investigator, those have a history of or currently have any diseases or conditions that may increase the risk of their participation in the trial, affect their compliance with the protocol, or affect their completion of the trial. These include, but are not limited to, diseases or conditions related to the respiratory, circulatory, digestive, urinary, hematological, endocrine, metabolic, nervous, mental, and immune systems.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cohort1:HS-10542 SAD:HS-10542 capsule

    Drug: HS-10542

  • Placebo comparator
    Cohort2:HS-10542 Placebo SAD:HS-10542 capsule placebo

    Drug: HS-10542 Placebo

  • Experimental
    Cohort3:HS-10542 MAD:HS-10542 capsule

    Drug: HS-10542

  • Placebo comparator
    Cohort4:HS-10542 Placebo MAD:HS-10542 capsule placebo

    Drug: HS-10542 Placebo

Interventions

  • 1. SAD:HS-10542 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1. 2. Food Effect \[FE\] study:HS-10542 capsule (in one predefined dose cohort ) will be administered orally once on Day 15.

  • DrugHS-10542 Placebo

    SAD:HS-10542 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1

  • MAD:HS-10542 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 10.

  • DrugHS-10542 Placebo

    MAD:HS-10542 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 10.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs) and the changes in clinical test and examination results

    The incidence and severity of adverse events (AEs), serious adverse events (SAEs), and adverse events leading to withdrawal from the study, as well as their correlation with the investigational drug.And the changes in clinical test and examination results before and after administration

    Time frame: From screening to day 11 or day 21.

Secondary outcomes

  1. Pharmacokinetics (PK) parameters:Observed maximum plasma concentration(Cmax)

    The plasma PK parameters to be determined after the first dose in the single ascending dose (SAD) and food effect (FE) studies

    Time frame: up to 240 hours after dosing

  2. Pharmacokinetics (PK) parameters:Time to reach maximum plasma concentration(Tmax)

    The plasma PK parameters to be determined after the first dose in the single ascending dose (SAD) and food effect (FE) studies

    Time frame: up to 240 hours after dosing

  3. Pharmacokinetics (PK) parameters:area under the concentration-time curve from time 0 to time t of last measurable concentration( AUC0-t)

    The plasma PK parameters to be determined after the first dose in the single ascending dose (SAD), food effect (FE), and multiple ascending dose (MAD) studies

    Time frame: up to 240 hours after dosing

  4. PK parameters: Maximum plasma concentration at steady state (Css, max)

    The plasma PK parameters to be determined after the last dose in the MAD study

    Time frame: up to 240 hours after dosing

  5. PK parameters: time to Css, max (Tss, max)

    The plasma PK parameters to be determined after the last dose in the MAD study

    Time frame: up to 240 hours after dosing

  6. PK parameters: Minimum plasma concentration at steady state (Css, min)

    The plasma PK parameters to be determined after the last dose in the MAD study

    Time frame: up to 240 hours after dosing

  7. PK parameters: Area under the plasma concentration-time curve over a dosing interval at steady state (AUCss)

    The plasma PK parameters to be determined after the last dose in the MAD study

    Time frame: up to 240 hours after dosing

  8. PK parameters: Apparent clearance at steady state (CLss/F)

    The plasma PK parameters to be determined after the last dose in the MAD study

    Time frame: up to 240 hours after dosing

  9. PK parameters: Apparent volume of distribution at steady state (Vss/F)

    The plasma PK parameters to be determined after the last dose in the MAD study

    Time frame: up to 240 hours after dosing

  10. PK parameters: Degree of accumulation after multiple doses (Rac)

    The plasma PK parameters to be determined after the last dose in the MAD study

    Time frame: up to 240 hours after dosing

  11. PK parameters: Elimination half-life (t½)

    The plasma PK parameters to be determined after the first dose in the single ascending dose (SAD), food effect (FE), and multiple ascending dose (MAD) studies

    Time frame: up to 240 hours after dosing

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2025, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
Jun 26, 2025
StartActual
May 16, 2025
Primary completionEst.
Dec 4, 2025
CompletionEst.
Mar 31, 2026
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07040046
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
May 16, 2025
Primary completion
Dec 4, 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Jun 26, 2025

Study contacts

Yu Cao
Contact
caoyu1767@126.com
18661809090

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10542

Start the discussion